Minneapolis, MN, United States of America

Walter C Low

USPTO Granted Patents = 13 

Average Co-Inventor Count = 3.9

ph-index = 5

Forward Citations = 95(Granted Patents)


Location History:

  • Saint Paul, MN (US) (2016)
  • Shorewood, MN (US) (1998 - 2018)
  • Minneapolis, MN (US) (2017 - 2022)

Company Filing History:


Years Active: 1998-2024

Loading Chart...
13 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Walter Low

Introduction: Walter Low, an esteemed inventor based in Shorewood, MN, has made significant strides in the field of biomedical innovation. He is recognized for his pioneering work in therapies targeting mucopolysaccharidosis type II, a serious genetic disorder.

Latest Patents: Walter Low holds a patent for "Methods to treat mucopolysaccharidosis type II or deficiency in iduronate-2-sulfatase using a recombinant adeno-associated virus (AAV) vector encoding iduronate-2-sulfatase." This innovative method aims to prevent, inhibit, or treat symptoms associated with diseases of the central nervous system by administering a recombinant AAV encoding a gene product that is either absent or present at reduced levels in affected mammals.

Career Highlights: Walter has contributed his expertise in various esteemed organizations, including the University of Minnesota and Regenxbio Inc. His work is at the forefront of developing treatments that harness gene therapy to address serious medical conditions.

Collaborations: Throughout his career, Walter Low has collaborated with notable colleagues such as R Scott McIvor and Lalitha R Belur. These collaborations have undoubtedly enriched the research environment and have propelled advancements in therapeutic methodologies for genetic disorders.

Conclusion: Walter Low continues to be an influential figure in the realm of medical inventions. His commitment to innovation and research exemplifies the essential role that inventors play in the advancement of science and medicine. His patented methods offer hope for improved treatment options for patients facing challenging genetic conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…